STOCK TITAN

Curevac B.V. Stock Price, News & Analysis

CVAC Nasdaq

Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.

CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.

Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.

Key updates cover:

• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications

Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
none
-
-
Rhea-AI Summary

CureVac N.V. (Nasdaq:CVAC) reported its financial results for the fourth quarter and full year 2022, showcasing a significant transformation in its operations driven by clinical advancements in COVID-19 and flu together with a broadened oncology footprint. The company achieved positive preliminary Phase 1 data for its modified COVID-19 candidate CV0501 and flu candidate Flu-SV-mRNA, demonstrating good tolerability and strong immune responses across age groups. CureVac ended 2022 with €495.8 million in cash, down from €811.5 million the previous year, driven by R&D expenditures. Revenue fell to €67.4 million from €103.0 million, primarily due to the cessation of collaborations and focused program adjustments. The operating loss for the year was €249.5 million, reflecting increased strategic investments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
Rhea-AI Summary

CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company based in Tübingen, Germany, is set to report its fourth quarter and full-year 2022 financial results on April 25, 2023. The company will also offer business updates during a conference call at 3 p.m. CET / 9 a.m. EST. Interested parties can join via U.S. Toll-Free number or through international dial-in options. A live webcast will also be available on the CureVac website. This announcement follows CureVac's notable history in developing mRNA technology, including a partnership with GSK for vaccine development. With over 20 years of expertise, CureVac continues to build a robust clinical pipeline targeting various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences earnings

FAQ

What is the current stock price of Curevac B.V. (CVAC)?

The current stock price of Curevac B.V. (CVAC) is $5.45 as of July 3, 2025.

What is the market cap of Curevac B.V. (CVAC)?

The market cap of Curevac B.V. (CVAC) is approximately 1.2B.
Curevac B.V.

Nasdaq:CVAC

CVAC Rankings

CVAC Stock Data

1.22B
96.00M
45.26%
18.01%
1.74%
Biotechnology
Healthcare
Link
Germany
Tübingen